Presentation is loading. Please wait.

Presentation is loading. Please wait.

A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25.

Published byChristoffer Sven-Erik Nilsson Modified over 5 years ago

Similar presentations

Presentation on theme: "A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25."— Presentation transcript:

1 A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. Subjects with NGT, IGT, or T2DM were administered GGIs with albumin alone (Alb), GIP alone (GIP), xenin-25 alone (Xen), or the combination of GIP plus xenin-25 (G+X). Group average values ± SEM for insulin, C-peptide, ISR, and glucose are shown. Burton M. Wice et al. Diabetes 2012;61: ©2012 by American Diabetes Association

Download ppt "A–L: Xenin-25 amplifies the effects of GIP on plasma insulin, C-peptide, and glucose levels and ISRs in humans with NGT and IGT but not T2DM. A–L: Xenin-25."

Similar presentations

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.

Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.
Philip J. Barter, et al. Circulation 2011;124:555-562.

Philip J. Barter, et al. Circulation 2011;124:
Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.

Infusion of Hi-Xen reduces the iAUCs for gastric emptying and postprandial glucose levels in humans with NGT, IGT, and T2DM. Infusion of Hi-Xen reduces.
Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.

Fig. 1. Intravenous glucose infusion rates during an isoglycemic intravenous glucose infusion (IIGI) study in subjects with (A) normal glucose tolerance.
Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.

Plasma insulin concentrations (A) and insulin secretion rates (B) in response to molar increments of plasma glucose concentration during the graded glucose.
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Insulin and glucagon secretion: nondiabetic and diabetic subjects.

Insulin and glucagon secretion: nondiabetic and diabetic subjects.
(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.

(A) Fasting serum glucose (mg/dL), (B) fasting serum insulin (μU/mL), (C) plasma glycated albumin (GA; %) and (D) plasma fructosamine (μmol/L) measured.
Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.

Flowchart of literature search for the effect of fructose on glycemic end points (fasting glucose, fasting insulin, and glycated blood proteins [HbA1c.
Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.

Impact of U-100 RHI administered with V-Go at OV1 (3 months after initiation) and OV2 (6 months after initiation) (n = 11) at 3 months (P = 0.32) and at.
Dandan Wang et al. BTS 2018;3:350-362 Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),

Dandan Wang et al. BTS 2018;3: Down-Regulation of miR-24 in Response to Insulin Infusion in Human Plasma Human plasma insulin (A), glucose (B),
Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.

Comparison of triglycerides AUC 480’ between IGT+reduced FPIS group, IGT+preserved FPIS group, and IGT+reduced FPIS+reduced FPIS and FPIS restitution with.
Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.

Cyp8b1−/− mice have improved islet insulin secretion and increased islet insulin content but unchanged β-cell mass. Cyp8b1−/− mice have improved islet.
Cyp8b1−/− mice have an altered circulating bile acid pool.

Cyp8b1−/− mice have an altered circulating bile acid pool.
Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.
A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.

A–F: Xenin-25 amplifies the insulin secretory response to GIP in humans with NGT and IGT but not T2DM. A–F: Xenin-25 amplifies the insulin secretory response.
A and B: Plasma levels of IR-GIP and xenin-25 during GGIs

A and B: Plasma levels of IR-GIP and xenin-25 during GGIs
The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.

The development of plasma (p-)C-peptide responses to an intravenous glucose (0.5 g glucose/kg body wt) and glucagon (1 mg) infusion test up to 5–7 years.
Glucose, insulin, and AGE levels during an OGC before and after RT

Glucose, insulin, and AGE levels during an OGC before and after RT
Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Changes (mean +SEM) in glucose, insulin, glucagon-like peptide (GLP)-1 and ghrelin from the baseline values after administration of placebo (broken lines.

Similar presentations

Ads by Google